Fig. 1.

A - Post-therapy images obtained in the anterior (left) and posterior (right) projections at 24 h after the administration of 4.6 GBq ¹⁷⁷Lu-PSMA (1st cycle) showing extremely high tumor burden in the skeletal system, resulting in negligible tracer activity in the kidneys and the intestine. B - Post-therapy images obtained in the anterior (left) and posterior (right) projections at 24 h after the administration of 4.4 GBq ¹⁷⁷Lu-PSMA (7th cycle) in the same patient, showing favourable treatment response as seen by the reduction in skeletal tumor burden, and visualization of tracer activity in the kidneys and the intestine. The patient showed a significant reduction in Serum PSA (from 2681 mcg/L to 40.1 mcg/L), alng with improvement in the bone marrow and renal function.